IL‐2mAb treatment slightly reduced the infiltration of CD3+ T cells, but significantly reduced the proportion of CD8+ T cells among CD3+ T cells in the ischemic brain 7 days after stroke (P < 0.05, Figure 4D). The gene discussed is CD8A; the disease is stroke disorder.